7RG0'un PB Oranı emsallerine kıyasla nasıldır?

7RG0, Price-To-Book değerine göre iyi bir değerdir. Eş ortalamaya (1.2x) kıyasla oran (12.8x).

7RG0'nin PB Oranı, DE Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

7RG0 Price-To-Book Oranı ( 1.2 x) baz alındığında, German Biotechs sektör ortalamasına ( 2 x) kıyasla iyi bir değerdir.

7RG0'nin PB Oranı, Adil PB Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PB Oranıdır.

Değerleme analizi için 7RG0 'in Price-To-Book Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında 7RG0 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

7RG0 'un değerleme analizi için adil değerinin hesaplanmasında yeterli veri bulunmamaktadır.

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Hedef fiyat, mevcut hisse senedi fiyatından % 20 daha yüksek, ancak analistler istatistiksel olarak güvenli bir mutabakat aralığında değil.

Regulus Therapeutics (DB:7RG0) - Hisse Senedi Fiyatı, Haberler ve Analizler

7RG0 Stoklara Genel Bakış

7RG0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda dalgalı hisse senedi fiyatı

Regulus Therapeutics Inc. Rakipler

4SC

DB:VSC

€50.2m

Heidelberg Pharma

XTRA:HPHA

€111.9m

Medigene

XTRA:MDG1

€16.7m

2invest

XTRA:2INV

€64.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Regulus Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.52
52 Haftanın En Yüksek Seviyesi	US$3.26
52 Haftanın En Düşük Seviyesi	US$1.02
Beta	1.63
11 Aylık Değişim	4.11%
3 Aylık Değişim	4.11%
1 Yıllık Değişim	27.73%
33 Yıllık Değişim	-48.99%
5 Yıllık Değişim	-78.13%
Halka arzdan bu yana değişim	-99.82%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	7RG0	DE Biotechs	DE Pazar
7D	16.0%	1.2%	0.9%
1Y	27.7%	-19.2%	7.7%

Getiri vs. Endüstri: 7RG0 geçen yıl % -19.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 7RG0 geçen yıl % 7.7 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 7RG0's price volatile compared to industry and market?
7RG0 volatility
7RG0 Average Weekly Movement	10.2%
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 7RG0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 7RG0 'nin haftalık oynaklığı son bir yılda 20% dan 10% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	32	Jay Hagan	www.regulusrx.com

Klinik aşamada bir biyofarmasötik şirketi olan Regulus Therapeutics Inc., Amerika Birleşik Devletleri'nde bir dizi hastalığı tedavi etmek için mikroRNA'ları hedefleyen ilaçların keşfi ve geliştirilmesine odaklanmaktadır. Ürün adayları arasında, otozomal dominant polikistik böbrek hastalığının tedavisi için Faz 1b klinik çalışmasında olan miR-17'yi hedefleyen bir anti-miR yeni nesil oligonükleotid olan RGLS8429 bulunmaktadır. Şirket ayrıca hedef organ seçici dağıtım stratejileri için preklinik ilaç ürünlerinden oluşan bir boru hattı geliştirmektedir.

Regulus Therapeutics Inc. Temel Bilgiler Özeti

Regulus Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
7RG0 temel i̇stati̇sti̇kler
Piyasa değeri	€99.66m
Kazançlar(TTM)	-€39.34m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.5x

F/K Oranı

7RG0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
7RG0 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$22.62m
Brüt Kâr	-US$22.62m
Diğer Giderler	US$19.01m
Kazançlar	-US$41.63m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.64
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

7RG0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

7RG0 Stoklara Genel Bakış

Risk Analizi

Regulus Therapeutics Inc. Rakipler

DB:VSC

€50.2m

XTRA:HPHA

€111.9m

XTRA:MDG1

€16.7m

XTRA:2INV

€64.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

New minor risk - Profitability

New major risk - Revenue and earnings growth

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

New minor risk - Profitability

New major risk - Revenue and earnings growth

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations

New 90-day high: €1.58

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: €1.32

New 90-day high: €0.84

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding

New 90-day high: €0.52

Revenue beats expectations

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

New 90-day low - €0.38

New 90-day low - €0.53